Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLS001 in papulopustular rosacea
NCT02576860Phase 3Completed
- Sponsor
- Maruho Co., Ltd.
- Start
- Oct 2015
- Primary completion
- Feb 2017
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of CLS001 topical gel vehicle in papulopustular rosacea (2 arms), sponsored by Maruho Co., Ltd. Primary endpoints: Absolute Change in Inflammatory Lesion Count at 12 weeks and Investigator's Global Assessment 2 Grade Reduction at 12 weeks. Started Oct 2015; status: completed.
02
Drugs
CLS001 topical gel vehicle
03
Conditions
papulopustular rosacea
Beyond the preview
Go deeper on NCT02576860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02576860.